Clinical significance of transforming growth factor beta 1, platelet-derived growth factor and vascular endothelial growth factor in diagnosis and evaluation of idiopathic pulmonary fibrosis

doi:10.3877/cma.j.issn.1674-6902.2020.01.011

Abstract

Abstract:

Objective

To investigate the expression and clinical significance of transforming growth factor beta 1 (TGFβ1), platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) in the patients with idiopathic pulmonary fibrosis (IPF).

Methods

A total of 35 IPF patients were selected who were admitted in our hospital from January 2014 to December 2018 as the IPF group and 18 patients with pulmonary sarcoidosis of Stage Ⅰ who were admitted in our hospital at the same period were taken as the control group. Firstly, Western blotting method was employed to observe whether the TGFβ1, PDGF and VEGF expressed in the serum. Secondly, the expression levels of TGFβ1, PDGF and VEGF in the bronchoalveolar lavage fluid (BALF) and in the serum were detected by enzyme-linked immunosorbent assay. Finally, the correlations of TGFβ1, PDGF and VEGF with the pulmonary functions and the blood oxygen saturation were analyzed.

Results

Expression of TGFβ1, PDGF and VEGF exists in the serum of the IPF patients. The expression levels of TGFβ1, PDGF and VEGF in the BALF and in the serum were significantly higher in the IPF group than the control group (P<0.05). The expression levels of TGFβ1, PDGF and VEGF in the BALF and in the serum were negatively correlated with FVC%, FEV₁% and DLCO%pred in the IPF group, while they were negatively correlated with the degree of blood oxygen saturation.

Conclusion

The expression levels of TGFβ1, PDGF and VEGF in the serum and in the BALF increase in the IPF patients. They are negatively correlated with the pulmonary functions and the degree of blood oxygen saturation, which can be used as a clinical effective marker for disease monitoring and severity evaluation.

Key words: Idiopathic pulmonary fibrosis, Transforming growth factor-β, Platelet derived growth factor, Vascular endothelial growth factor

ying Sun, yang Peifu, wei Sun. Clinical significance of transforming growth factor beta 1, platelet-derived growth factor and vascular endothelial growth factor in diagnosis and evaluation of idiopathic pulmonary fibrosis[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(01): 54-58.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2020.01.011

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2020/V13/I01/54

Figures/Tables 5

References 20

1	崔社怀. 特发性肺间质纤维化的回顾和展望[J/CD]. 中华肺部疾病杂志(电子版), 2010, 3(1): 4-5.
2	Wu Q, Zhou Y, Feng FC, et al. Effectiveness and safety of Chinese medicine for Idiopathic pulmonary fibrosis: A systematic review and meta-analysis[J]. Chin J integr Med, 2019, 25(10): 778-784.
3	Marshall DC, Salciccioli JD, Shea BS, et al. Trends in mortality from idiopathic pulmonary fibrosis in the European Union: an Observational study of the WHO mortality database from 2001-2013[J]. EurRespir J, 2018, 51(1): 1701603.
4	Gannon W, Lederer DJ, Biscotti M, et al. Outcomes and mortality prediction model of critically ill adults with acute respiratory failure and interstitial lung disease[J]. Chest, 2018, 3692(18): 30078-30073.
5	Kreuter M, Costabel U, Richeldi L, et al. Statin therapy and outcomes in trials of Nintedanib in Idiopathic pulmonary fibrosis[J]. Respiration, 2018, 95(5): 317-326.
6	Gabasa M, Duch P, Jorba I, et al. Epithelial contribution to the profibrotic stiff microenvironment and myofibroblast population in lung fibrosis[J]. Mol Biol Cell, 2017, 28(26): 3741-3755.
7	Li LC, Xu L, Hu Y, et al. Astragaloside Ⅳ improves bleomycin-induced pulmonary fibrosis in rats by attenuating extracellular matrix deposition[J]. Front Pharmacol, 2017, 8(8): 513.
8	Nyp MF, Mabry SM, Navarro A, et al. Lung epithelial-specific TRIP-1 overexpression maintains epithelial integrity during hyperoxia exposure[J]. Physiol Rep, 2018, 6(5): doi: 10.14814/phy2.13585.
9	Zheng S, Wang Q, D′Souza V, et al. Resolvin D stimulates epithelial wound repair andinhibitsTGF-β-induced EMT whilst reducing fibroproliferation and collagen production[J]. Lab Invest, 2018, 98(1): 130-140.
10	Kishi M, Aono Y, Sato S, et al. Blockade of platelet-derived growth factor receptor-β，not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice[J]. PLoS One, 2018, 13(12): e0209786.
11	Barratt SL, Blythe T, Ourradi K, et al. Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in idiopathic pulmonary Fibrosis (IPF)[J]. Respir Res, 2018, 19(1): 9.
12	Povedano JM, Martinez P, Serrano R, et al. Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres[J]. Elife, 2018, 30(7): e31299.
13	Torrisi SE, Palmucci S, Stefano A, et al. Assessment of survival in patients with idiopathic pulmonary fibrosis using quantitative HRCT indexes[J]. Multidiscip Respir Med, 2018, 1(13): 43.
14	Yu SH, Liu LJ, Lv B, et al. Inhibition of bleomycin-induced pulmonary fibrosis by bone marrow-derived mesenchymal stem cells might be mediated by decreasing MMP9, TIMP-1, INF-γ and TGF-β[J]. Cell Biochem Funct, 2015, 33(6): 356-366.
15	Ronan N, Bennett DM, Khan KA, et al. Tissue and Bronchoalveolar lavage biomarkers in idiopathic pulmonary fibrosis patients on pirfenidone[J]. Lung, 2018, 196(5): 543-552.
16	Alsumrain M, De Giacomi F, Nasim F, et al. Combined pulmonary fibrosis and emphysema as a clinicoradiologic entity: Characterization of presenting lung fibrosis and implications for survival[J]. Respir Med, 2019, 146: 106-112.
17	Ramos-Rossy J, Cantres-Fonseca O, Arzon-Nieves G, et al. Misleading diagnosis of idiopathic pulmonary fibrosis: A clinical concern[J]. Fed Pract, 2018, 35(2): 40-42.
18	Xie T, Liang J, Geng Y, et al. MicroRNA-29c prevents pulmonary fibrosis by regulating epithelial cell renewal and apoptosis[J]. Am J Respir Cell Mol Biol, 2017, 57(6): 721-732.
19	Kropski JA, Blackwell TS. Progress in understanding and treating Idiopathic Pulmonary Fibrosis[J]. Annu Rev Med, 2019, 27(70): 211-224.
20	Kolilekas L, Papiris S, Bouros D. Existing and emerging treatments for idiopathic pulmonary fibrosis[J]. Expert Rev Respir Med, 2019, 13(3): 229-239.

组　别	例数	BALF液
组　别	例数	TGF-β1(μ/ml)	PDGF(μ/ml)	VEGF(μ/ml)
IPF组	35	523.27±285.68	465.01±187.71	329.08±107.71
对照组	18	206.03±109.87	185.01±123.71	129.01±106.09
t值		5.013	4.203	3.403
P值		0.000	0.000	0.000

组　别	例数	BALF液
组　别	例数	TGF-β1(μ/ml)	PDGF(μ/ml)	VEGF(μ/ml)
IPF组	35	523.27±285.68	465.01±187.71	329.08±107.71
对照组	18	206.03±109.87	185.01±123.71	129.01±106.09
t值		5.013	4.203	3.403
P值		0.000	0.000	0.000

组　别	例数	血清
组　别	例数	TGF-β1(μ/ml)	PDGF(μ/ml)	VEGF(μ/ml)
IPF组	35	823.27±405.76	700.78±377.54	590.12±221.23
对照组	18	346.03±219.87	290.01±213.06	227.01±195.29
t值		7.513	6.783	5.723
P值		0.000	0.000	0.000

组　别	例数	血清
组　别	例数	TGF-β1(μ/ml)	PDGF(μ/ml)	VEGF(μ/ml)
IPF组	35	823.27±405.76	700.78±377.54	590.12±221.23
对照组	18	346.03±219.87	290.01±213.06	227.01±195.29
t值		7.513	6.783	5.723
P值		0.000	0.000	0.000

指　标	FEV₁%		FVC%		DLCO%		PaO₂(mmHg)
指　标	γ	P	γ	P	γ	P	γ	P
BALF
TGF-β1	-0.674	0.000	-0.523	0.000	-0.411	0.000	-2.589	0.000
PDGF	-0.576	0.000	-0.489	0.000	-0.401	0.000	-1.109	0.000
VEGF	-0.441	0.000	-0.378	0.000	-0.281	0.000	-0.351	0.000
血清
TGF-β1	-0.805	0.000	-0.752	0.000	-0.602	0.000	-0.619	0.000
PDGF	-0.685	0.000	-0.616	0.000	-0.495	0.000	-0.551	0.000
VEGF	-0.521	0.000	-0.508	0.000	-0.389	0.000	-0.267	0.000

Please choose a citation manager

Content to export